|
(ÁÖ)Áö¿À¿µ |
ÀǾàÇ°À¯Åë Ç°Áú°ü¸®¾à»ç ä¿ë
ÀÎõ ¼±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.10 |
|
|
Çѱ¹Organon |
Çѱ¹Organon-Market Access Specialist 1¸í ¸ðÁý
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
12.04 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Oncology MSL 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
10.31 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD RA Specialist Á¤±ÔÁ÷ ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.31 |
|
|
Çѱ¹MSD ÁÖ½Äȸ»ç |
ID/Vaccine MSL ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
Çѱ¹¿¥¿¡½ºµð ÁÖ½Äȸ»ç |
[Çѱ¹MSD] MSL-ID/Vaccine
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
08.13 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)RA Specialist 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.13 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO-Study Authorization Associate (1¸í)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
09.23 |
|
|
½ÌÅ©ÅÊÅ©(ÁÖ) |
¿Ü±¹°èÁ¦¾àȸ»ç ÀÓ»ó±âȹ °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
02.15 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
RA Specialist ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
06.20 |
|
|
°³²Â÷º´¿ø |
°³²Â÷º´¿ø ¾ß°£¾à»ç Ãʺù ¾È³»
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
05.11 |
|
|
Çѱ¹Organon |
Çѱ¹Organon Market Access ´ã´çÀÚ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
01.15 |
|
|
°Ç°Á¦Àϳì½ÊÀھ౹ |
±Ù¹«¾à»ç´Ô ¸ð½Ê´Ï´Ù
¼¿ï µµºÀ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
10.15 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO- Jr. CRA (5¸í ä¿ë)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
09.21 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Diabetes Medical Lead
¼¿ï ¼Ãʱ¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.20 |
|